Rogaratinib (BAY1163877) in Chinese Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

April 30, 2019

Study Completion Date

April 14, 2020

Conditions
Neoplasms
Interventions
DRUG

Rogaratinib (BAY1163877)

Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.

Trial Locations (1)

100730

Beijing Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03788603 - Rogaratinib (BAY1163877) in Chinese Patients | Biotech Hunter | Biotech Hunter